Stoke completes Zorevunersen Phase 3 enrollment
Stoke Therapeutics reported completing enrollment for the zorevunersen Phase 3 EMPEROR study involving 162 patients. The biotech firm plans a U.S. NDA submission in early 2027 and targets a potential launch by 2028.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day